Open in interactive viewer → charts, metric popovers & call review

Afya: The Margin Is in Medicine, the Story Is Everywhere Else

A +6% revenue quarter and 44% EBITDA margin are the easy part — the hard part is a two-year wait for the digital segments to pay for themselves, and a December exam result that could reset 2027.
AFYA · Earnings Call · 2026-11-12

Undergrad pays the bills; the small segments absorb the spend

Afya's third quarter of 2026 was, on the surface, unremarkable in the best way. Revenue rose 6% year-over-year to BRL 985 million; adjusted EBITDA rose 9% to BRL 434 million; the margin expanded 100 basis points to 44%. Across nine months, revenue reached BRL 2,970 million (+7%), EBITDA BRL 1,352 million (+5%) at a 45.5% margin, and net income BRL 634 million (+7%), with EPS up 9% to BRL 6.98 thanks to the buyback. Cash conversion held near 100% — 99.5% — with BRL 629 million of free cash flow to equity. The composition is what matters. Undergraduate revenue was BRL 2,642 million of the nine-month total — roughly 89% — and 85% of that came from medicine, 93% from health-related courses. Medical seats grew 5% to 3,785, the medical student base crossed 26,000 (+3%), and net average ticket rose 4% to BRL 9,466. average tickets in the core franchise are still moving with, or slightly ahead of, inflation. Meanwhile Continuing Education revenue was BRL 209 million, up just 1%, and Medical Practice Solutions was BRL 128 million, flat. Both were deliberately pushed into an investment cycle late last year — product build, technology, sales teams — and both compressed gross margin this quarter. Consolidated margin expansion came entirely from undergrad, where the company is diluting fixed costs, packing more students per class and combining health disciplines across programs to reduce faculty cost. So the optics are flattered by the 89% that is working. The story is in the 11% that is being rebuilt.

A two-year wait, stated with unusual honesty

Flavio Yoshida of Bank of America asked the right question: the student base keeps growing but revenue per student does not, so when does monetization catch up? Virgilio Gibbon did not sugarcoat it:

We are growing faster the student base... the mix effect here is that we have much more student applying for short duration programs, more related to procedure, new technicals for some specialties. And that -- the consequence direction of that is that the revenue does not come because the tuition is much lower.

Virgilio Deloy Gibbon, CEO · 2026-11-12
He then dated the recovery to 2027-2028 for continuing education revenue per student to stabilize in the low single digits. That is a two-year wait in a company that the market has historically valued as a maturing med-school roll-up, not a platform transition. The volume is genuinely there. The student base in continuing education grew 10% over nine months; other B2P and B2B offerings grew 17%; the undergraduate journey grew 2%; and the residency segment was down 4% year-over-year but up 4% sequentially on seasonality. In Medical Practice Solutions, active payers rose 2% to roughly 206,000, with clinical management payers up 20% to 52,000 on iClinic penetration, while monthly active users slipped 4%. That user decline is not new. The Q2 call attributed it to AI tools pressuring Whitebook's payer count — the decline on Whitebook was flagged explicitly in August — and to a deliberate repricing of the freemium/premium mix. Management is now investing to embed AI features and rebuild engagement, which is precisely the investment cycle that is suppressing segment margins today.

ENAMED: the overhang that may be quietly lifting

This is the freshest thing in the quarter. Brazil's revised medical-school exam — the new ENAMED — penalized underperforming campuses last cycle, and in March management was careful, saying the 2026 impact would be near zero only because the intake was already booked, while the rules remained a live risk for 2027. The tone has changed. Asked about preliminary results, Gibbon said Afya's students were almost 20 percentage points above last year's exam on an unnormalized simple average — 18 points on a normalized basis — across every campus. Results are due in December. And crucially, there was no cost attached: “We didn't have any additional cost from ENAMED. We are doing 100% internally... We run at least 11 mocks for every campuses.” — Virgilio Deloy Gibbon, CEO · 2026-11-12 If December confirms it, the penalties that capped seats at some campuses reset for the 2027 intake — which would convert a regulatory overhang into an ENAMED exam tailwind ahead of next year's guidance.

FIES, guidance, and the quiet beat that isn't being raised

Working capital is the one visible blemish. FIES receivables rose 64% versus December, about BRL 90 million, pushing receivable days up. Gibbon frames it as a sector-wide timing issue from late amendments and contract renewals; Blanco expects the position to be flat to lower next year, with FIES around 22% of medical students. Cash conversion stuck at 99.5% is the rebuttal. Guidance was reaffirmed in identical language to August: “We will deliver the guidance that we provided to the market in the beginning of the year.” — Luis Andre Blanco, CFO · 2026-11-12 That is the same phrase Blanco used two quarters ago when he said: “we are focused on delivering the EBITDA that we provided to the market that's between BRL 1.7 billion and BRL 1.8 billion.” — Luis Andre Blanco, Chief Financial Officer (CFO) · 2026-08-13 And in March, the year was framed as roughly 190 basis points of margin compression versus 2025. Q3 delivered +100 basis points. The company is comfortably beating its own cautious setup and declining to raise — a classic setup for a March 2027 reset. One small positive worth noting: the gross tuition increase passed for 2027 is 5.7%, above the 5%-5.2% flagged a year ago, and occupancy remains 100%. health programs and Health science students grew 18%, diversifying beyond medicine. The average cost of debt, average cost of debt at 15.2% (roughly 106% of CDI), is high in absolute terms, but duration was extended from 1.9 to 3.7 years and net debt sits at 0.7x EBITDA excluding IFRS 16 — a genuinely conservative profile.

What to watch

December's ENAMED result is the first real catalyst: confirm the internal read and the 2027 intake narrative changes. March brings 2027 guidance and the first real test of whether the investment cycle ends on schedule. In between, watch continuing-education revenue per student, FIES receivable normalization, and whether Medical Practice Solutions active users inflect. The quarter itself was solid but not story-changing — the story is being deferred, and management has now told you exactly how long they want you to wait.